CorMedix (CRMD) Income from Non-Controlling Interests (2024 - 2025)
CorMedix (CRMD) reported Income from Non-Controlling Interests of -$13.9 million for Q4 2025, down 3.48% on a YoY basis from -$14.4 million in Q4 2024, and up 87.16% sequentially from -$108.6 million in Q3 2025.
CorMedix (CRMD) Income from Non-Controlling Interests (2024 - 2025) Analysis & Trends
CorMedix (CRMD) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$13.9 million in Q4 2025.
- For the quarter ending Q4 2025, Income from Non-Controlling Interests fell 3.48% year-over-year to -$13.9 million; the trailing twelve-month figure through Dec 2025 stood at -$163.0 million (down 1008.75% YoY), and the FY2025 full-year result was -$163.0 million, down 1008.75% from the prior year.
- Income from Non-Controlling Interests climbed to -$13.9 million in Q4 2025, from -$108.6 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $14.5 million in Q1 2024 to a low of -$108.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | - |
| 10 | CorMedix | 4.94 Mn | -150.26 Mn | 107.31 Mn | -13.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.94 Mn |
| Sep 30, 2025 | -108.57 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Mar 31, 2025 | -20.64 Mn |
| Dec 31, 2024 | -13.47 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 14.15 Mn |
| Mar 31, 2024 | 14.48 Mn |